单唾液酸四己糖神经节苷脂治疗急性脑出血

Treatment of acute intracerebral hemorrhage by monosialotetrahexosylganglioside

目的探讨单唾液酸四己糖神经节苷脂(GM1)治疗急性脑出血的疗效。方法将76例急性脑出血患者分为治疗组与对照组,观察并比较GM1及常规治疗对2组患者的美国国立卫生研究院卒中量表(NIHSS)和改良Rankin评分(mRS)的影响。结果与基线水平相比,2组患者治疗后1月的NIHSS评分和治疗后3月的MRS评分差异均有统计学意义(P<0.05或P<0.01)。治疗组的NIHSS及mRS评分改善程度优于对照组(P均<0.01)。结论 GM1对急性脑出血治疗可能有效。

Objective To observe the effect of monosialotetrahexosylganglioside(GM1) in acute intracerebral hemorrhage.Methods Seventy-six patients with acute intracerebral hemorrhage were divided into the treatment group and the control group,their National Institute of Health Stroke Scale(NIHSS) and Modified Rankin score(mRS) were observed and compared each other.Results Compared with the baseline scores,two group patients had great changes of the score of NIHSS after one month,and great changes of the score of mRS after three months,respectively(P<0.05 or P<0.01).Compared with the control group,the treatment group had greater changes of the score of NIHSS and the score of mRS(all P<0.01).Conclusion The GM1 may have benefit effect for treating acute intracerebral hemorrhage.